Diabetes can be described as a syndrome of multiple closely related conditions induced by a chronic state of hyperglycaemia resulting from defective insulin secretion, insulin action or both. Chronic complications associated with diabetes (including neuropathy, vascular disease, nephropathy and retinopathy) are common, and of these, erectile dysfunction (ED) deserves special attention. ED and its correlation with cardiovascular disease require careful evaluation and appropriate treatment. PDE5 inhibitors (PDE5is) are an important tool for the treatment of ED, with new drugs coming onto the market since the late 90s. This review offers an overview of PDE5is and their use in treating ED in diabetes. We underline the differences between different types of PDE5i, focusing on available doses, duration of action, T ½, side effects and selectivity profiles in relation to patients with diabetes. We also discuss the link between diabetes and ED in presence of various associated cofactors (obesity, hypertension and its pharmacological treatments, atherosclerosis, hyperhomocysteinaemia, neuropathy, nephropathy, hypogonadism and depression). Finally a number of past and ongoing clinical trials on the use of PDE5is in patients with diabetes are presented to offer an overview of the appropriate treatment of ED in this condition.

Erectile dysfunction and its management in patients with diabetes mellitus / Defeudis, Giuseppe; Gianfrilli, Daniele; Di Emidio, Chiara; Pofi, Riccardo; Tuccinardi, Dario; Palermo, Andrea; Lenzi, Andrea; Pozzilli, Paolo. - In: REVIEWS IN ENDOCRINE & METABOLIC DISORDERS. - ISSN 1389-9155. - 16:3(2015), pp. 213-231. [10.1007/s11154-015-9321-4]

Erectile dysfunction and its management in patients with diabetes mellitus

DEFEUDIS, GIUSEPPE;GIANFRILLI, DANIELE;POFI, RICCARDO;LENZI, Andrea;
2015

Abstract

Diabetes can be described as a syndrome of multiple closely related conditions induced by a chronic state of hyperglycaemia resulting from defective insulin secretion, insulin action or both. Chronic complications associated with diabetes (including neuropathy, vascular disease, nephropathy and retinopathy) are common, and of these, erectile dysfunction (ED) deserves special attention. ED and its correlation with cardiovascular disease require careful evaluation and appropriate treatment. PDE5 inhibitors (PDE5is) are an important tool for the treatment of ED, with new drugs coming onto the market since the late 90s. This review offers an overview of PDE5is and their use in treating ED in diabetes. We underline the differences between different types of PDE5i, focusing on available doses, duration of action, T ½, side effects and selectivity profiles in relation to patients with diabetes. We also discuss the link between diabetes and ED in presence of various associated cofactors (obesity, hypertension and its pharmacological treatments, atherosclerosis, hyperhomocysteinaemia, neuropathy, nephropathy, hypogonadism and depression). Finally a number of past and ongoing clinical trials on the use of PDE5is in patients with diabetes are presented to offer an overview of the appropriate treatment of ED in this condition.
2015
Diabetes complications; Diabetes mellitus; Erectile dysfunction; PDE-5 inhibitors; Endocrinology; Endocrinology, Diabetes and Metabolism
01 Pubblicazione su rivista::01a Articolo in rivista
Erectile dysfunction and its management in patients with diabetes mellitus / Defeudis, Giuseppe; Gianfrilli, Daniele; Di Emidio, Chiara; Pofi, Riccardo; Tuccinardi, Dario; Palermo, Andrea; Lenzi, Andrea; Pozzilli, Paolo. - In: REVIEWS IN ENDOCRINE & METABOLIC DISORDERS. - ISSN 1389-9155. - 16:3(2015), pp. 213-231. [10.1007/s11154-015-9321-4]
File allegati a questo prodotto
File Dimensione Formato  
Defeudis_Erectile-dysfunction_2015.pdf

accesso aperto

Note: articolo principale
Tipologia: Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 750.75 kB
Formato Adobe PDF
750.75 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/853490
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 33
  • ???jsp.display-item.citation.isi??? 31
social impact